Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

As GLP-1 receptor agonists are currently widely used in clinical practice to treat obesity/type 2 diabetes, it is necessary to determine the effects of GLP-1 on the reproductive system in humans.

To investigate the effects of GLP-1 administration on the reproductive axis in humans.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, men only.

Eighteen healthy men (mean age 24.7 ± 0.1years, mean BMI 22.1 ± 0.4kg/m2).

How the Study Was Run

The design is described as randomized, single-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

In this single-blind Glucagon study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

Single-blind, randomized, placebo-controlled crossover study.

Clinical Research Facility, Imperial College Healthcare NHS Trust.

What Was Measured

The subject headings attached to it are Biomarkers, Glucagon, Glucagon-Like Peptide 1, Incretins, Insulin Secretion, Prognosis and Reproduction.

Author keywords: follicle stimulating hormone, glucagon-like peptide-1, luteinizing hormone and testosterone.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Glucagon.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Glucagon compound page, all human trials.